Mono-cationic detergents play a critical role in the development of liposome-based gene vector via controlling its lamellarity
Source abstract
Abstract
Controlling the number of lipid bilayers, the lamellarity, in a liposome is a major factor in the in vivo/in vitro pharmacokinetics of drug delivery using liposome-based nanocarriers. Findings reported in a previous study indicated that a mono-cationic detergent (MCD) could be useful in controlling liposomal size via interaction with the lipid envelope. Here, we investigated controlling the lamellarity of the liposomal gene vector by MCD, using a multifunctional envelope-type nano device (MEND). The MEND consisted of a condensed plasmid DNA core and lipid envelopes. The size of the MCD-contained MEND (MCD-MEND) decreased as a function of the amount of MCD, indicating that MCD can be used to control the number of the lipid bilayers. We also developed a triple-layered MEND (TL-MEND) by packaging a di-lamellar MEND into an MCD-containing lipid bilayer. We hypothesized that the TL-MEND would efficiently deliver a gene to the nucleus, when the outer single bilayer fused with the plasma membrane and the inner double membranes then fused with the nuclear double membranes. Transfection assays showed that the TL-MEND had a high transfection activity in JAWS II cells, non-dividing cells. These results indicate that MCD has the potential for enhancing the gene delivery by controlling liposomal lamellarity.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · DNA and Nucleic Acid Chemistry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB (2005) The liposomal formulation of doxorubicin. Method Enzymol 391:71–9710.1016/S0076-6879(05)91004-5 ↗
2. Akita H, Kudo A, Minoura A, Yamaguti M, Khalil IA, Moriguchi R, Masuda T, Danev R, Nagayama K, Kogure K, Harashima H (2009) Multi-layered nanoparticles for penetrating the endosome and nuclear membrane via a step-wise membrane fusion process. Biomaterials 30(15):2940–294910.1016/j.biomaterials.2009.02.009 ↗
3. Akita H, Kogure K, Moriguchi R, Nakamura Y, Higashi T, Nakamura T, Serada S, Fujimoto M, Naka T, Futaki S, Harashima H (2011) Reprint of: nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. J Control Release 149(1):58–64. doi: 10.1016/j.jconrel.2010.08.02310.1016/j.jconrel.2010.08.023 ↗
4. Bunjes H (2010) Lipid nanoparticles for the delivery of poorly water-soluble drugs. J Pharm Pharmacol 62(11):1637–1645. doi: 10.1111/j.2042-7158.2010.01024.x10.1111/j.2042-7158.2010.01024.x ↗
5. Faraji AH, Wipf P (2009) Nanoparticles in cellular drug delivery. Bioorg Med Chem 17(8):2950–2962. doi: 10.1016/j.bmc.2009.02.04310.1016/j.bmc.2009.02.043 ↗
6. Fattahi H, Laurent S, Liu FJ, Arsalani N, Elst LV, Muller RN (2011) Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine-Uk 6(3):529–544. doi: 10.2217/Nnm.11.1410.2217/nnm.11.14 ↗
7. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, Ueda K, Harashima H, Sugiura Y (2001) Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 12(6):1005–101110.1021/bc015508l ↗
8. Gupta B, Levchenko TS, Torchilin VP (2005) Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57(4):637–651. doi: 10.1016/j.addr.2004.10.00710.1016/j.addr.2004.10.007 ↗
9. Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM (2011) Nanoparticles as contrast agents for in vivo bioimaging: current status and future perspectives. Anal Bioanal Chem 399(1):3–27. doi: 10.1007/s00216-010-4207-510.1007/s00216-010-4207-5 ↗
10. Huang HC, Barua S, Sharma G, Dey SK, Rege K (2011) Inorganic nanoparticles for cancer imaging and therapy. J Control Release 155(3):344–357. doi: 10.1016/j.jconrel.2011.06.00410.1016/j.jconrel.2011.06.004 ↗
11. Kamal MM, Mills D, Grzybek M, Howard J (2009) Measurement of the membrane curvature preference of phospholipids reveals only weak coupling between lipid shape and leaflet curvature. Proc Natl Acad Sci USA 106(52):22245–22250. doi: 10.1073/pnas.090735410610.1073/pnas.0907354106 ↗
12. Kamaly N, Xiao ZY, Valencia PM, Radovic-Moreno AF, Farokhzad OC (2012) Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41(7):2971–3010. doi: 10.1039/C2cs15344k10.1039/c2cs15344k ↗
13. Kawamura E, Yamada Y, Yasuzaki Y, Hyodo M, Harashima H (2013) Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide. J Biosci Bioeng 116(5):634–637. doi: 10.1016/j.jbiosc.2013.05.00110.1016/j.jbiosc.2013.05.001 ↗
14. Khalil IA, Kogure K, Futaki S, Harashima H (2006) High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 281(6):3544–3551. doi: 10.1074/jbc.M50320220010.1074/jbc.M503202200 ↗
15. Khalil IA, Kogure K, Futaki S, Hama S, Akita H, Ueno M, Kishida H, Kudoh M, Mishina Y, Kataoka K, Yamada M, Harashima H (2007) Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther 14(8):682–68910.1038/sj.gt.3302910 ↗
16. Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H (2004) Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release 98(2):317–323. doi: 10.1016/j.jconrel.2004.04.02410.1016/j.jconrel.2004.04.024 ↗
17. Kogure K, Akita H, Yamada Y, Harashima H (2007) Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. Adv Drug Deliv Rev 60(4–5):559–571
18. Lasic DD (1988) The mechanism of vesicle formation. Biochem J 256(1):1–1110.1042/bj2560001 ↗
19. Matsumura Y, Kataoka K (2009) Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 100(4):572–579. doi: 10.1111/j.1349-7006.2009.01103.x10.1111/j.1349-7006.2009.01103.x ↗
20. McIntyre JC, Sleight RG (1991) Fluorescence assay for phospholipid membrane asymmetry. Biochemistry 30(51):11819–1182710.1021/bi00115a012 ↗
21. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA (1981) Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 20(4):833–84010.1021/bi00507a028 ↗
22. Nagle JF, Tristram-Nagle S (2000) Structure of lipid bilayers. Biochim Biophys Acta 1469(3):159–19510.1016/S0304-4157(00)00016-2 ↗
23. Nakamura T, Akita H, Yamada Y, Hatakeyama H, Harashima H (2012) A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Acc Chem Res 45(7):1113–1121. doi: 10.1021/ar200254s10.1021/ar200254s ↗
24. Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y, Takehashi M, Tanaka S, Ueda K, Simpson JC, Jones AT, Sugiura Y, Futaki S (2004) Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 10(6):1011–1022. doi: 10.1016/j.ymthe.2004.08.01010.1016/j.ymthe.2004.08.010 ↗
25. Nishiyama N, Kataoka K (2006) Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Therapeut 112(3):630–648. doi: 10.1016/j.pharmthera.2006.05.00610.1016/j.pharmthera.2006.05.006 ↗
26. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760. doi: 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
27. Reischl D, Zimmer A (2009) Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomed-Nanotechnol 5(1):8–20. doi: 10.1016/j.nano.2008.06.00110.1016/j.nano.2008.06.001 ↗
28. Sasaki K, Kogure K, Chaki S, Kihira Y, Ueno M, Harashima H (2005) Construction of a multifunctional envelope-type nano device by a SUV*-fusion method. Int J Pharm 296(1–2):142–150. doi: 10.1016/j.ijpharm.2005.02.02010.1016/j.ijpharm.2005.02.020 ↗
29. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG (2010) Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267(1):9–21. doi: 10.1111/j.1365-2796.2009.02189.x10.1111/j.1365-2796.2009.02189.x ↗
30. Suzuki R, Yamada Y, Harashima H (2008) Development of small, homogeneous pDNA particles condensed with mono-cationic detergents and encapsulated in a multifunctional envelope-type nano device. Biol Pharm Bull 31(6):1237–124310.1248/bpb.31.1237 ↗
31. Tabakovic A, Kester M, Adair JH (2012) Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. Wires Nanomed Nanobi 4(1):96–112. doi: 10.1002/Wnan.16310.1002/wnan.163 ↗
32. Tandia BM, Vandenbranden M, Wattiez R, Lakhdar Z, Ruysschaert JM, Elouahabi A (2003) Identification of human plasma proteins that bind to cationic lipid/DNA complex and analysis of their effects on transfection efficiency: implications for intravenous gene transfer. Mol Ther 8(2):264–27310.1016/S1525-0016(03)00150-3 ↗
33. Wheeler JJ, Palmer L, Ossanlou M, MacLachlan I, Graham RW, Zhang YP, Hope MJ, Scherrer P, Cullis PR (1999) Stabilized plasmid-lipid particles: construction and characterization. Gene Ther 6(2):271–281. doi: 10.1038/sj.gt.330082110.1038/sj.gt.3300821 ↗